Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Castle Biosciences to $38 from $42 and keeps an Outperform rating on the shares. The analyst continues to think the valuation gap versus. peers is overdone given the company’s growth profile/balance sheet and believes shares could get working again once we have clarity on the path forward for DecisionDx-SCC Medicare reimbursement.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CSTL:
- Castle Biosciences reports Q4 EPS (78c), consensus (84c)
- Castle Biosciences management to meet virtually with Stephens
- Castle up 1.5% after announcing presentation for dermatology conference
- Castle to share data on clinical value skin cancer test at Hawaii conference
- Castle Biosciences expects to meet or exceed guided FY22 revenue of $132M-$137M
